An Overview of Atopic Dermatitis

Video

Transcript:

Peter A. Lio, MD: What is atopic dermatitis? It’s an interesting entity. It is a chronic, itchy, inflammatory skin condition that affects lots of people, from kids to older adults. It’s interesting because it has a number of clinical presentations, so it can look a little different across different individuals, and even in the same individual at different times. But it’s brought together by this particular characteristic look to it overall, this eczematous format as we call it, and it also is notable to be always itchy. It really has to be itchy to be definitionally called atopic dermatitis. Finally, it has to be chronic.

It’s often used synonymously with the term eczema, but they’re not true synonyms. Eczema is a broader category and it refers to that characteristic pattern or morphology that we can see in the skin. There are other types of eczema that fall under that heading, including atopic dermatitis, which is the most common, and why it’s shorthand. But things like contact dermatitis, dyshidrotic eczema, nummular eczema, seborrheic dermatitis, and stasis dermatitis can also be considered eczematous dermatoses.

Is there a particular age of onset? Yes. The majority of patients, probably more than 80%, maybe even 90% depending on the population studied, will present with atopic dermatitis before the age of 5 years. When you look at it as a population, it’s predominantly a pediatric disease. But that is not everybody. A significant number of patients develop it much later in life, and even some older adults develop it. Typically younger patients, but it can happen anytime in life.

Then the question often comes up, is this going to be persistent? Will my child grow out of it? Will I grew out of it. The truth is that we think some component of patients, particularly those who are more mild, tend to improve with time. However, not everybody does. We think that at least a third of patients—maybe higher, depending on how you ask the question and what population you’re looking at—may have persistent disease through childhood into adulthood. It does seem to skew toward those who are more severe. That’s why it’s so important that we never poo-poo it and say, “Oh, don’t worry, you’re eventually going to grow out of this.” We have many patients who are frustrated and feeling really angry because they did not grow out of it.

Transcript Edited for Clarity


Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
© 2024 MJH Life Sciences

All rights reserved.